Glucotrack (Nasdaq:GCTK) President and CEO Paul V. Goode today issued a statement to shareholders outlining strategic changes.
Goode’s letter to shareholders announced a redefined strategic direction. The company wants to move closer to becoming a leader in the diabetes market.
According to Goode, the diabetes market has undergone a transformation over recent years. He attributed that to the growth of continuous glucose monitoring (CGM), shifting focus from point-in-time glucose monitoring. With that market shift, Glucotrack intends to shift its own focus from non-invasive, non-continuous glucose monitoring. It now aims to bolster the CGM technology within its portfolio.
Get the full story at our sister site, Drug Delivery Business News.